［1］ XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants ［J］.Chin Med J (Engl),2022,135(5):584-590.
［2］ KIM YA,LEE YR,PARK J,et al.Socioeconomic burden of cancer in Korea from 2011 to 2015 ［J］.Cancer Res Treat,2020,52(3):896-906.
［3］ JOHANNSEN L,BRANDT M,FRERICHS W,et al.The impact of cancer on the mental health of patients parenting minor children:A systematic review of quantitative evidence ［J］.Psychooncology,2022,31(6):869-878.
［4］ HE H,NI J,HUANG J.Molecular mechanisms of chemoresistance in osteosarcoma (Review) ［J］.Oncol Lett,2014,7(5):1352-1362.
［5］ JANICZEK-POLEWSKA M,SZYLBERG L,MALICKI J,et al.Role of interleukins and new perspectives in mechanisms of resistance to chemotherapy in gastric cancer ［J］.Biomedicines,2022,10(7):1600.
［6］ FRANTZI M,VAN KESSEL KE,ZWARTHOFF EC,et al.Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study ［J］.Clin Cancer Res,2016,22(16):4077-4086.
［7］ LEITE ML,DA CUNHA NB,COSTA FF.Antimicrobial peptides,nanotechnology,and natural metabolites as novel approaches for cancer treatment ［J］.Pharmacol Ther,2018,183:160-176.
［8］ 张志慧,苏秀兰.生物活性肽在医药领域的研究进展 ［J］.中国医药导报,2019,16(10):37-40.
ZHANG ZH,SU XL.Research progress of bioactive peptides in the field of medicine［J］.China Medical Herald，2019,16(10):37-40.
［9］ MOTTAGHI-DASTJERDI N,SOLTANY-REZAEE-RAD M,SEPEHRIZADEH Z,et al.Genome expression analysis by suppression subtractive hybridization identified overexpression of Humanin,a target gene in gastric cancer chemoresistance［J］.DARU,2014,22(1):14.
［10］ GUO B,ZHAI D,CABEZAS E,et al.Humanin peptide suppresses apoptosis by interfering with Bax activation［J］.Nature,2003,423(6938):456-461.
［11］ AL-SALAM S,SUDHADEVI M,AWWAD A,et al.Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy ［J］.BMC Cancer,2019,19(1):135.
［12］赵喆,白桦,王志杰,等.肿瘤微环境与免疫治疗耐药的关系及应对［J］.现代肿瘤医学， 2020,28(22):3985-3989.
ZHAO Zhe,BAI Hua,WANG Zhijie,et al.Coping strategies for the relationship between tumor microenvironment and immunotherapy resistance［J］.Modern Oncology,2020,28(22):3985-3989.
［13］赵婷婷,张清媛.PD-1/PD-L1介导的肿瘤免疫逃逸在肿瘤微环境中的研究进展［J］.现代肿瘤医学，2021,29(03):520-523.
ZHAO Tingting,ZHANG Qingyuan.Advances in research of PD-1/PD-L1 mediated tumor immune escape in tumor microenvironment［J］.Modern Oncology,2021,29(03):520-523.
［14］ PILLOZZI S,MASSELLI M,DE LORENZO E,et al.Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers ［J］.Blood,2011,117(3):902-914.
［15］ PILLOZZI S,BERNINI A,SPIGA O,et al.Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrowinduced chemoresistance in acute leukemias ［J］.Oncol Rep,2019,41(1):312-324.
［16］ BEIDER K,DARASH-YAHANA M,BLAIER O,et al.Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo ［J］.Mol Cancer Ther,2014,13(5):1155-1169.
［17］ CHO BS,ZENG Z,MU H,et al.Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy ［J］.Blood,2015,126(2):222-232.
［18］ GONZALEZ-GONZALEZ L,ALONSO J.Periostin:a matricellular protein with multiple functions in cancer development and progression ［J］.Front Oncol,2018,8:225.
［19］ LIU Y,HUANG Z,CUI D,et al.The multiaspect functions of periostin in tumor progression ［J］.Adv Exp Med Biol,2019,1132:125-136.
［20］ OO KK,KAMOLHAN T,SONI A,et al.Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer ［J］.BMC Cancer,2021,21(1):65.
［21］ PANKOV R,YAMADA KM.Fibronectin at a glance ［J］.J Cell Sci,2002,115(Pt 20):3861-3863.
［22］ ERDOGAN B,AO M,WHITE LM,et al.Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin ［J］.J Cell Biol,2017,216(11):3799-3816.
［23］ AMRUTKAR M,AASRUM M,VERBEKE CS,et al.Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells ［J］.BMC Cancer,2019,19(1):596.
［24］ ZHANG Z,ZHANG Y,QIN X,et al.FGF9 promotes cisplatin resistance in colorectal cancer via regulation of Wnt/beta-catenin signaling pathway ［J］.Exp Ther Med,2020,19(3):1711-1718.
［25］ RAO C,MIAO X,ZHAO G,et al.miR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9 ［J］.Biomed Pharmacother,2019,114:108662.
［26］ WANG J,TAN X,GUO Q,et al.FGF9 inhibition by a novel binding peptide has efficacy in gastric and bladder cancer per se and reverses resistance to cisplatin ［J］.Pharmacol Res,2020,152:104575.
［27］ LI D,ZHOU L,HUANG J,et al.Effect of multidrug resistance 1/P-glycoprotein on the hypoxia-induced multidrug resistance of human laryngeal cancer cells ［J］.Oncol Lett,2016,12(2):1569-1574.
［28］ HASSAN VENKATESH G,BRAVO P,SHAABAN MOUSTAFA ELSAYED W,et al.Hypoxia increases mutational load of breast cancer cells through frameshift mutations ［J］.Oncoimmunology,2020,9(1):1750750.
［29］ BELL EN,TSE MY,FREDERIKSEN LJ,et al.Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells ［J］.J Urol,2007,177(2):751-756.
［30］ LV K,LIU L,WANG L,et al.Lin28 mediates paclitaxel resistance by modulating p21,Rb and Let-7a miRNA in breast cancer cells ［J］.PLoS One,2012,7(7):e40008.
［31］ YAN BX,MA JX,ZHANG J,et al.PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer ［J］.Oncogene,2014,33(45):5288-5294.
［32］ TODARO M,LOMBARDO Y,FRANCIPANE MG,et al.Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4 ［J］.Cell Death Differ,2008,15(4):762-772.
［33］ TODARO M,ALEA MP,DI STEFANO AB,et al.Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4 ［J］.Cell Stem Cell,2007,1(4):389-402.
［34］ GURUPRASATH P,KIM J,GUNASSEKARAN GR,et al.Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth ［J］.Biomaterials,2017,142:101-111.
［35］ CHI L,NA MH,JUNG HK,et al.Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells ［J］.J Control Release,2015,209:327-336.
［36］ PERMPOON U,KHAN F,VADEVOO SMP,et al.Inhibition of tumor growth against chemoresistant cholangiocarcinoma by a proapoptotic peptide targeting interleukin-4 receptor ［J］.Mol Pharm,2020,17(11):4077-4088.
［37］ LAW B,QUINTI L,CHOI Y,et al.A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity ［J］.Mol Cancer Ther,2006,5(8):1944-1949.
［38］ JING L,QU H,WU D,et al.Platelet-camouflaged nanococktail:Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy ［J］.Theranostics,2018,8(10):2683-2695.
［39］ DU C,FANG M,LI Y,et al.Smac,a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition ［J］.Cell Adh Migr,2000,102(1):33-42.
［40］ SUN Q,ZHENG X,ZHANG L,et al.Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway ［J］.Clin Cancer Res,2011,17(8):2361-2372.
［41］ WANG H,WANG H,LIANG J,et al.Cell-penetrating apoptotic peptide/p53 DNA nanocomplex as adjuvant therapy for drug-resistant breast cancer ［J］.Mol Pharm,2014,11(10):3352-3360.
［42］ CHOI CH,SUNG CO,KIM HJ,et al.Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary ［J］.Hum Pathol,2013,44(6):1017-1023.
［43］ KIM A,ENOMOTO T,SERADA S,et al.Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin ［J］.Int J Cancer,2009,125(10):2316-2322.
［44］ GAUDIO E,PADUANO F,SPIZZO R,et al.Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel ［J］.PLoS One,2013,8(11):e78610.
［45］ GAUDIO EPF,NGANKEU A,ORTUSO F,et al.A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells ［J］.Oncotarget 2016,7(21):29927-29936.
［46］ AKIZUKI R,MARUHASHI R,EGUCHI H,et al.Decrease in paracellular permeability and chemosensitivity to doxorubicin by claudin-1 in spheroid culture models of human lung adenocarcinoma A549 cells ［J］.Biochim Biophys Acta Mol Cell Res,2018,1865(5):769-780.
［47］ NASAKO H,TAKASHINA Y,EGUCHI H,et al.Increase in toxicity of anticancer drugs by PMTPV,a Claudin-1-binding peptide,mediated via down-regulation of Claudin-1 in human lung adenocarcinoma A549 cells ［J］.Int J Mol Sci,2020,21(16):5909.
［48］ MARUHASHI R,AKIZUKI R,SATO T,et al.Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models ［J］.Biochim Biophys Acta Mol Cell Res,2018,1865(3):470-479.
［49］ NASAKO H,AKIZUKI R,TAKASHINA Y,et al.Claudin-2 binding peptides,VPDSM and DSMKF,down-regulate claudin-2 expression and anticancer resistance in human lung adenocarcinoma A549 cells ［J］.Biochim Biophys Acta Mol Cell Res,2020,1867(4):118642.
［50］ MUNOZ JL,RODRIGUEZ-CRUZ V,GRECO SJ,et al.Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43 ［J］.Cell Death Dis,2014,5:e1145.
［51］ MURPHY SF,VARGHESE RT,LAMOUILLE S,et al.Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide ［J］.Cancer Res,2016,76(1):139-149.
［52］ PRIDHAM KJ,SHAH F,HUTCHINGS KR,et al.Connexin 43 confers chemoresistance through activating PI3K ［J］.Oncogenesis,2022,11(1):2.
［53］ WOJTASZEK JL,CHATTERJEE N,NAJEEB J,et al.A small molecule targeting mutagenic translesion synthesis improves chemotherapy ［J］.Cell,2019,178(1):152-159,e11.
［54］ CHATTERJEE N,D'SOUZA S,SHABAB M,et al.A stapled POL kappa peptide targets REV1 to inhibit mutagenic translesion synthesis ［J］.Environ Mol Mutagen,2020,61(8):830-836.